| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
Revenue  | 137 | 155 | 159 | 180 | 166 | 179 | 185 | 178 | 175 | 203 | 209 | 221 | 223 | 237 | 238 | 266 | 254 | 284 | 300 | 316 | 335 | 352 | 357 | 393 | 402 | 447 | 448 | 467 | 447 | 479 | 522 | 554 |
| Expenses | 103 | 116 | 125 | 139 | 125 | 132 | 135 | 131 | 125 | 143 | 146 | 159 | 157 | 173 | 179 | 202 | 202 | 210 | 214 | 224 | 234 | 253 | 249 | 282 | 281 | 305 | 310 | 321 | 298 | 329 | 389 | 424 |
| EBITDA | 35 | 39 | 35 | 41 | 41 | 47 | 50 | 47 | 50 | 60 | 63 | 63 | 66 | 64 | 59 | 64 | 51 | 74 | 86 | 92 | 101 | 99 | 108 | 112 | 121 | 142 | 138 | 146 | 149 | 150 | 132 | 130 |
| Operating Profit % | 23 % | 23 % | 20 % | 20 % | 23 % | 24 % | 25 % | 23 % | 27 % | 28 % | 28 % | 25 % | 26 % | 23 % | 22 % | 22 % | 19 % | 24 % | 25 % | 27 % | 27 % | 25 % | 27 % | 26 % | 27 % | 27 % | 27 % | 27 % | 26 % | 26 % | 21 % | 21 % |
| Depreciation | 9 | 9 | 10 | 10 | 10 | 10 | 11 | 10 | 11 | 11 | 13 | 13 | 13 | 14 | 14 | 14 | 14 | 14 | 14 | 15 | 16 | 16 | 16 | 16 | 20 | 21 | 21 | 21 | 23 | 25 | 29 | 38 |
| Interest | 4 | 7 | -1 | 2 | 3 | 2 | 5 | 8 | 3 | 3 | 5 | -2 | 3 | 0 | -1 | 2 | 1 | 0 | 5 | 2 | 3 | 2 | 4 | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 6 | 6 |
| Profit Before Tax | 22 | 23 | 26 | 30 | 28 | 36 | 34 | 29 | 36 | 46 | 46 | 52 | 50 | 50 | 46 | 49 | 36 | 59 | 67 | 75 | 83 | 81 | 88 | 93 | 99 | 118 | 113 | 123 | 123 | 122 | 98 | 85 |
| Tax | 9 | 9 | 10 | 8 | 8 | 7 | 9 | 6 | 10 | 11 | 11 | 13 | 13 | 12 | 11 | 13 | 9 | 16 | 17 | 16 | 20 | 19 | 23 | 24 | 24 | 31 | 28 | 31 | 30 | 30 | 27 | 20 |
| Net Profit | 13 | 15 | 16 | 22 | 20 | 28 | 25 | 23 | 27 | 35 | 35 | 39 | 38 | 38 | 35 | 36 | 27 | 44 | 50 | 59 | 63 | 62 | 65 | 68 | 74 | 87 | 85 | 92 | 93 | 92 | 71 | 65 |
| EPS in ₹ | 1.50 | 1.65 | 1.82 | 2.44 | 2.24 | 3.22 | 2.83 | 2.57 | 3.03 | 3.97 | 4.00 | 4.26 | 3.92 | 3.99 | 3.60 | 3.77 | 2.81 | 4.53 | 5.21 | 6.13 | 6.54 | 6.48 | 6.78 | 7.12 | 7.71 | 9.01 | 8.48 | 8.92 | 9.19 | 9.06 | 7.00 | 6.54 |
Poly Medicure
Poly Medicure
1,324.40
-9.50
(-0.71%)
Market Cap
13,424.05 Cr
PE Ratio
42.21
Volume
94,822.00
Day High - Low
1,330.80 - 1,300.00
52W High-Low
2,316.60 - 1,182.00
There are 1 new updates from the company19 hrs ago
View
Key Fundamentals
Market Cap
13,424.05 Cr
EPS
31.79
PE Ratio
42.21
PB Ratio
4.36
Book Value
306.45
EBITDA
435.51
Dividend Yield
0.26 %
Industry
Healthcare Sector
Medical Equipment Return on Equity
12.24
Debt to Equity
0.08
Analyst Rating and Forecast
- By Refinitiv from5 analysts
Actual
Company News
View All News
Poly Medicure appointed Mr. Indranil Mukherjee as Chief Executive Officer - Asia Pacific and India Business effective June 1, 2026.
Poly Medicure Q4 Revenue Rises but Profit Declines YoY7 days ago
Poly Medicure reports Q4 revenue of 5.3B rupees vs 4.4B YoY, while net profit fell to 663M rupees from 918M and EBITDA margin contracted to 20.7% from 27%.
Poly Medicure grants 17,500 ESOPs
9 days ago
9 days agoPoly Medicure granted 17,500 stock options at INR 100 per share under its ESOS 2020. Options vest over four years after a one-year cliff.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,324.40 | #1 13,424.05 | #5 42.21 | #1 1,875.26 | #8 6.61 | #1 326 | #4 -29.19 | 37.21 | |
235.77 | 1,295.84 | 43.74 | 271.50 | 12.00 | 22 | #1 134.88 | 58.50 | |
208.01 | 1,106.74 | 77.51 | 422.51 | 3.45 | 16 | -58.82 | 47.17 | |
467.00 | 826.34 | 28.26 | 292.67 | 56.84 | 30 | - | 32.88 | |
443.00 | 768.02 | 75.74 | 278.87 | 10.97 | 10 | -68.29 | 55.58 | |
153.18 | 680.90 | #1 17.64 | 410.77 | 22.29 | 36 | 46.36 | 44.05 | |
390.00 | 508.53 | 27.71 | 231.81 | #1 107.34 | 19 | - | 61.69 | |
388.10 | 465.86 | 22.79 | 71.81 | 7.02 | 21 | 13.73 | 41.94 | |
158.50 | 301.78 | 55.99 | 54.75 | -59.83 | 5 | - | 30.29 | |
241.30 | 230.25 | 109.72 | 146.96 | 20.36 | 3 | -344.00 | 34.37 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
6.61 %
Net Income Growth
-3.72 %
Cash Flow Change
-9.64 %
ROE
-30.34 %
ROCE
-30.22 %
EBITDA Margin (Avg.)
-29.37 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 | 3,193 | 3,919 |
| Fixed Assets | 166 | 182 | 207 | 265 | 306 | 363 | 426 | 488 | 635 | 867 | 1,084 | 1,519 |
| Current Assets | 160 | 171 | 205 | 255 | 302 | 318 | 704 | 783 | 807 | 842 | 1,917 | 1,942 |
| Capital Work in Progress | 10 | 14 | 20 | 18 | 19 | 25 | 21 | 43 | 78 | 76 | 101 | 91 |
| Investments | 0 | 0 | 3 | 17 | 8 | 25 | 354 | 346 | 126 | 167 | 1,077 | 434 |
| Other Assets | 189 | 191 | 227 | 264 | 321 | 354 | 422 | 499 | 738 | 749 | 930 | 0 |
| Total Equity & Liabilities | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 | 3,193 | 3,919 |
| Current Liabilities | 113 | 109 | 114 | 123 | 154 | 197 | 171 | 227 | 293 | 351 | 370 | 576 |
| Non Current Liabilities | 55 | 50 | 72 | 104 | 119 | 135 | 87 | 63 | 42 | 37 | 57 | 194 |
| Total Equity | 196 | 229 | 272 | 338 | 381 | 435 | 966 | 1,088 | 1,242 | 1,470 | 2,766 | 3,106 |
| Reserve & Surplus | 174 | 207 | 227 | 294 | 337 | 391 | 918 | 1,040 | 1,194 | 1,422 | 2,715 | 3,056 |
| Share Capital | 22 | 22 | 44 | 44 | 44 | 44 | 48 | 48 | 48 | 48 | 51 | 51 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -2 | 1 | 0 | 3 | 1 | 1 | 0 | 3 | -1 | 5 | -3 |
| Investing Activities | -59 | -31 | -56 | -88 | -101 | -110 | -436 | -85 | -179 | -241 | -1,194 |
| Operating Activities | 63 | 63 | 56 | 75 | 107 | 131 | 119 | 124 | 191 | 266 | 240 |
| Financing Activities | -6 | -31 | -0 | 16 | -5 | -21 | 317 | -35 | -13 | -20 | 951 |
Share Holding
| % Holding | Feb 2021 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Aug 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
| Promoter | 44.88 % | 44.88 % | 44.77 % | 44.77 % | 44.76 % | 44.66 % | 53.34 % | 53.33 % | 53.33 % | 53.31 % | 53.31 % | 53.16 % | 53.16 % | 53.15 % | 66.03 % | 62.56 % | 62.56 % | 62.44 % | 62.44 % | 62.44 % | 62.42 % | 62.42 % | 62.42 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 14.49 % | 0.00 % | 12.38 % | 9.91 % | 11.10 % | 11.87 % | 12.33 % | 11.46 % | 11.41 % | 9.77 % | 9.40 % | 5.91 % |
| DIIs | 1.83 % | 1.92 % | 2.68 % | 2.73 % | 2.86 % | 3.18 % | 3.10 % | 3.20 % | 3.38 % | 3.68 % | 4.25 % | 5.15 % | 5.28 % | 7.22 % | 9.35 % | 12.48 % | 12.33 % | 11.66 % | 11.96 % | 11.72 % | 13.54 % | 13.84 % | 15.59 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 16.24 % | 15.11 % | 14.24 % | 13.69 % | 13.24 % | 12.32 % | 11.93 % | 11.20 % | 11.18 % | 11.12 % | 11.10 % | 11.35 % | 11.38 % | 11.34 % | 11.37 % | 10.70 % | 10.14 % | 10.55 % | 11.08 % | 11.37 % | 11.25 % | 11.30 % | 12.61 % |
| Others | 37.06 % | 38.10 % | 38.30 % | 38.81 % | 39.14 % | 39.84 % | 31.63 % | 32.27 % | 32.11 % | 31.90 % | 31.34 % | 15.85 % | 30.17 % | 15.92 % | 3.36 % | 3.16 % | 3.10 % | 3.03 % | 3.07 % | 3.07 % | 3.02 % | 3.04 % | 3.47 % |
| No of Share Holders | 0 | 19,187 | 21,531 | 35,922 | 33,678 | 35,166 | 33,831 | 33,296 | 34,239 | 35,393 | 36,141 | 34,649 | 36,053 | 36,712 | 36,852 | 40,516 | 38,352 | 60,686 | 65,583 | 71,142 | 64,400 | 67,750 | 73,414 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 2.5 | 2 | 2 | 2 | 2.5 | 2.5 | 3 | 3 | 3.5 | 0.00 |
| Dividend Yield (%) | 1 | 0.91 | 0.86 | 0.24 | 0.26 | 0.27 | 0.19 | 0.13 | 0.29 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 28 Mar 2017 |  Bonus | 1:1 | 24 Mar 2017 | 0.00 | 0.00 |
| 17 Sept 2021 |  Dividend | ₹ 2.50 /share | 16 Sept 2021 | 1,136.45 | 956.25 |
| 19 Sept 2022 | Dividend | ₹ 2.50 /share | 16 Sept 2022 | 717.35 | 929.70 |
| 22 Sept 2023 | Dividend | ₹ 3.00 /share | 21 Sept 2023 | 978.85 | 1,411.50 |
| 20 Sept 2024 | Dividend | ₹ 3.00 /share | 19 Sept 2024 | 1,653.80 | 2,465.30 |
| 26 Sept 2024 |  Annual General Meeting | NA | 26 Sept 2024 | 2,502.15 | 2,317.00 |
| 28 Oct 2024 |  Quarterly Result Announcement | NA | 28 Oct 2024 | 2,452.50 | 2,515.05 |
| 03 Feb 2025 | Quarterly Result Announcement | NA | 03 Feb 2025 | 2,442.30 | 2,428.85 |
| 06 May 2025 | Quarterly Result Announcement | NA | 06 May 2025 | 2,588.50 | 2,591.10 |
| 08 Aug 2025 | Quarterly Result Announcement | NA | 08 Aug 2025 | 2,057.50 | 1,936.20 |
| 18 Sept 2025 | Dividend | ₹ 3.50 /share | 18 Sept 2025 | 2,591.10 | 1,996.15 |
| 25 Sept 2025 | Annual General Meeting | NA | 25 Sept 2025 | 2,068.95 | 1,983.10 |
| 08 Nov 2025 | Quarterly Result Announcement | NA | 08 Nov 2025 | 1,974.10 | 1,893.30 |
| 05 Feb 2026 | Quarterly Result Announcement | NA | 05 Feb 2026 | 1,513.80 | 1,517.20 |
| 25 May 2026 | Quarterly Result Announcement | NA | 25 May 2026 | 1,597.70 | 1,598.75 |
Announcements
Announcement under Regulation 30 (LODR)-Change in Management19 hrs ago
19 hrs agoAnnouncement under Regulation 30 (LODR)-Earnings Call Transcript3 days ago
3 days agoInvestors Call Scheduled To Be Held On 27 May 2026 Is Cancelled - Updates On Call6 days ago
6 days agoCompliances-Reg.24(A)-Annual Secretarial Compliance6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication6 days ago
6 days agoDeclaration Of Unmodified Opinion On The Audited Financial Results(Standalone & Consolidated) For The Quarter And Year Ended For The 31St March 20267 days ago
7 days agoStatement Of Deviation & Variation For The Quarter Ended On 31St March 20267 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Investor Presentation7 days ago
7 days agoAudited Financial Results (Standalone & Consolidated) For The Quarter And Financial Year Ended 31St March 20267 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Dividend Updates7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Dividend Updates7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Investor Presentation7 days ago
7 days agoBoard Meeting Outcome for Poly Medicure Limited Has Submitted To The Exchange The Audited Financial Results(Standalone & Consolidated) For The Quarter And Year Ended March 31 2026.7 days ago
7 days agoGrant Of Stock Options- Disclosure Under Regulation 30 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations 201510 days ago
10 days agoIntimation Of Investor/Analyst CallsMay 21, 2026
May 21, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 20, 2026
May 20, 2026Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 15, 2026
May 15, 2026Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 25Th May 2026May 14, 2026
May 14, 2026Announcement under Regulation 30 (LODR)-AcquisitionApr 30, 2026
Apr 30, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 15, 2026
Apr 15, 2026Closure of Trading WindowMar 27, 2026
Mar 27, 2026Poly Medicure Limited Has Informed The Exchange About Investors/Analysts Call Schedule On 30Th March 2026Mar 25, 2026
Mar 25, 2026Poly Medicure Limited Has Informed The Exchange About Investors/Analysts Call Schedule On 24Th March 2026 And Cancellation Of Investors/Analysts Call Scheduled On 20Th March 2026Mar 19, 2026
Mar 19, 2026Poly Medicure Limited Has Informed The Exchange About Investors/Analysts Call/Meet On 20Th March 2026Mar 17, 2026
Mar 17, 2026Poly Medicure Limited Has Informed The Exchange About Investors/Analysts Call/Meet On 19Th March 2026Mar 12, 2026
Mar 12, 2026Poly Medicure Limited Has Informed The Exchange About Investors/Analysts Call/Meet On 18Th March 2026Mar 10, 2026
Mar 10, 2026Poly Medicure Limited Has Informed The Exchange About Investors/Analysts Call/Meet On 09Th March 2026 And 10Th March 2026.Mar 07, 2026
Mar 07, 2026Announcement under Regulation 30 (LODR)-Investor PresentationMar 07, 2026
Mar 07, 2026Intimation Of Analysts/Investors Meet To Be Held On 9Th And 10Th March 2026Mar 03, 2026
Mar 03, 2026Intimation Of Analysts/Investors Meet To Be Held On 6Th March 2026Mar 02, 2026
Mar 02, 2026Intimation Of Analysts/Investors Call To Be Held On 02Nd March 2026Feb 28, 2026
Feb 28, 2026Announcement under Regulation 30 (LODR)-Monitoring Agency ReportFeb 13, 2026
Feb 13, 2026Statement Of Deviation And Variation For The Quarter Ended 31St December 2025Feb 13, 2026
Feb 13, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 11, 2026
Feb 11, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 06, 2026
Feb 06, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 06, 2026
Feb 06, 2026Announcement under Regulation 30 (LODR)-Investor PresentationFeb 05, 2026
Feb 05, 2026Grant Of 2000 Stock Options Under ESOS 2020 Of The Company.Feb 05, 2026
Feb 05, 2026Unaudited Financial Results (Standalone & Consolidated) For The Third Quarter And Nine Months Ended On 31St December 2025.Feb 05, 2026
Feb 05, 2026Board Meeting Outcome for Otcome Of Board Meeting Held On Today I.E. 05Th February 2026Feb 05, 2026
Feb 05, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 31, 2026
Jan 31, 2026Board Meeting Intimation for Intimation For The Board Meeting To Be Held On 05Th February 2026 For Consider And Approve The Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Nine Months Ended On 31St December 2025.Jan 29, 2026
Jan 29, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 13, 2026
Jan 13, 2026Clarification On Increase In VolumeJan 07, 2026
Jan 07, 2026Clarification sought from Poly Medicure LtdJan 07, 2026
Jan 07, 2026Closure of Trading WindowDec 29, 2025
Dec 29, 2025Investors/Analysts Virtual CallDec 18, 2025
Dec 18, 2025Intimation Of Investors/Analyst Virtual CallsNov 22, 2025
Nov 22, 2025Intimation Of Investors/Analyst Virtual Call On 24Th November 2025Nov 20, 2025
Nov 20, 2025Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 37.21
ATR(14)
Less Volatile 74.03
STOCH(9,6)
Neutral 22.82
STOCH RSI(14)
Oversold 2.83
MACD(12,26)
Bearish -31.70
ADX(14)
Weak Trend 23.41
UO(9)
Bearish 37.03
ROC(12)
Downtrend And Accelerating -16.51
WillR(14)
Oversold -94.74
About Poly Medicure
Poly Medicure Limited is an Indian medical device manufacturer founded in 1995. The company produces over 130 SKUs of medical devices across various product verticals including infusion therapy, oncology, anesthesia, respiratory care, urology, gastroenterology, blood management, surgery, and dialysis. Poly Medicure operates ten manufacturing facilities across India, China, Egypt, and...more
Website
Chairperson NameDevendra Raj Mehta
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
